Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges.
Rodríguez F, Caruana P, De la Fuente N, Español P, Gámez M, Balart J, Llurba E, Rovira R, Ruiz R, Martín-Lorente C, Corchero JL, Céspedes MV. Rodríguez F, et al. Among authors: martin lorente c. Biomolecules. 2022 Jun 4;12(6):784. doi: 10.3390/biom12060784. Biomolecules. 2022. PMID: 35740909 Free PMC article. Review.
SEOM clinical guideline in ovarian cancer (2020).
Redondo A, Guerra E, Manso L, Martin-Lorente C, Martinez-Garcia J, Perez-Fidalgo JA, Varela MQ, Rubio MJ, Barretina-Ginesta MP, Gonzalez-Martin A. Redondo A, et al. Among authors: martin lorente c. Clin Transl Oncol. 2021 May;23(5):961-968. doi: 10.1007/s12094-020-02545-x. Epub 2021 Jan 30. Clin Transl Oncol. 2021. PMID: 33515422 Free PMC article.
Management of advanced ovarian cancer in Spain: an expert Delphi consensus.
Redondo A, Oaknin A, Rubio MJ, Barretina-Ginesta MP, de Juan A, Manso L, Romero I, Martin-Lorente C, Poveda A, Gonzalez-Martin A. Redondo A, et al. Among authors: martin lorente c. J Ovarian Res. 2021 May 26;14(1):72. doi: 10.1186/s13048-021-00816-x. J Ovarian Res. 2021. PMID: 34039386 Free PMC article.
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
Francis KE, Kim SI, Friedlander M, Gebski V, Ray-Coquard I, Clamp A, Penson RT, Oza A, Perri T, Huzarski T, Martin-Lorente C, Cecere SC, Colombo N, Ataseven B, Fujiwara K, Sonke G, Vergote I, Pujade-Lauraine E, Kim JW, Lee CK. Francis KE, et al. Among authors: martin lorente c. Ann Oncol. 2022 Jun;33(6):593-601. doi: 10.1016/j.annonc.2022.02.222. Epub 2022 Feb 24. Ann Oncol. 2022. PMID: 35219776 Free article. Clinical Trial.
Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.
Castellano DE, Bellmunt J, Maroto JP, Font-Pous A, Morales-Barrera R, Ghanem I, Suarez C, Martín Lorente C, Etxaniz O, Capdevila L, Coronado C, Alfaro V, Siguero M, Fernández-Teruel C, Carles J. Castellano DE, et al. Cancer Chemother Pharmacol. 2014 Apr;73(4):857-67. doi: 10.1007/s00280-014-2419-7. Epub 2014 Feb 26. Cancer Chemother Pharmacol. 2014. PMID: 24570330 Clinical Trial.
Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021.
Tapia JC, Bosma F, Gavira J, Sanchez S, Molina MA, Sanz-Beltran J, Martin-Lorente C, Anguera G, Maroto P. Tapia JC, et al. Among authors: martin lorente c. Clin Genitourin Cancer. 2024 Feb 1;22(3):102047. doi: 10.1016/j.clgc.2024.01.019. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 38430859
Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy: a Spanish single-centre retrospective analysis.
Tapia JC, Gavira J, Anguera G, Sanchez S, Romano A, Bosma F, Molina A, Sanz-Beltran J, Martin-Lorente C, Algaba F, Maroto P. Tapia JC, et al. Among authors: martin lorente c. Clin Transl Oncol. 2024 Feb 29. doi: 10.1007/s12094-024-03393-9. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38421563
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, du Bois A, Lorusso D, Romero I, Petru E, Yoshida H, Vergote I, Colombo N, Hietanen S, Provansal M, Schmalfeldt B, Pignata S, Martín Lorente C, Berton D, Runnebaum IB, Ray-Coquard I. Pujade-Lauraine E, et al. Among authors: martin lorente c. JCO Precis Oncol. 2023 Jan;7:e2200258. doi: 10.1200/PO.22.00258. JCO Precis Oncol. 2023. PMID: 36716415 Free PMC article. Clinical Trial.
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martín-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard IL. Labidi-Galy SI, et al. Among authors: martin lorente c. Ann Oncol. 2023 Feb;34(2):152-162. doi: 10.1016/j.annonc.2022.11.003. Epub 2022 Nov 28. Ann Oncol. 2023. PMID: 36564284 Free article.
11 results